These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 32057371)
1. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. Baber U; Zafar MU; Dangas G; Escolar G; Angiolillo DJ; Sharma SK; Kini AS; Sartori S; Joyce L; Vogel B; Farhan S; Gurbel P; Gibson CM; Fuster V; Mehran R; Badimon JJ J Am Coll Cardiol; 2020 Feb; 75(6):578-586. PubMed ID: 32057371 [TBL] [Abstract][Full Text] [Related]
2. Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. Hennigan BW; Good R; Adamson C; Parker WAE; Martin L; Anderson L; Campbell M; Serruys PW; Storey RF; Oldroyd KG Platelets; 2022 Jan; 33(1):141-146. PubMed ID: 33356730 [TBL] [Abstract][Full Text] [Related]
3. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. Vogel B; Baber U; Cohen DJ; Sartori S; Sharma SK; Angiolillo DJ; Farhan S; Goel R; Zhang Z; Briguori C; Collier T; Dangas G; Dudek D; Escaned J; Gil R; Han YL; Kaul U; Kornowski R; Krucoff MW; Kunadian V; Mehta SR; Moliterno D; Ohman EM; Sardella G; Witzenbichler B; Gibson CM; Pocock S; Huber K; Mehran R JAMA Cardiol; 2021 Sep; 6(9):1032-1041. PubMed ID: 33991416 [TBL] [Abstract][Full Text] [Related]
4. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. Baber U; Dangas G; Cohen DJ; Gibson CM; Mehta SR; Angiolillo DJ; Pocock SJ; Krucoff MW; Kastrati A; Ohman EM; Steg PG; Badimon J; Zafar MU; Chandrasekhar J; Sartori S; Aquino M; Mehran R Am Heart J; 2016 Dec; 182():125-134. PubMed ID: 27914492 [TBL] [Abstract][Full Text] [Related]
5. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. Mehran R; Baber U; Sharma SK; Cohen DJ; Angiolillo DJ; Briguori C; Cha JY; Collier T; Dangas G; Dudek D; Džavík V; Escaned J; Gil R; Gurbel P; Hamm CW; Henry T; Huber K; Kastrati A; Kaul U; Kornowski R; Krucoff M; Kunadian V; Marx SO; Mehta SR; Moliterno D; Ohman EM; Oldroyd K; Sardella G; Sartori S; Shlofmitz R; Steg PG; Weisz G; Witzenbichler B; Han YL; Pocock S; Gibson CM N Engl J Med; 2019 Nov; 381(21):2032-2042. PubMed ID: 31556978 [TBL] [Abstract][Full Text] [Related]
14. Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Han Y; Claessen BE; Chen SL; Chunguang Q; Zhou Y; Xu Y; Hailong L; Chen J; Qiang W; Zhang R; Luo S; Li Y; Zhu J; Zhao X; Cheng X; Wang J; Su X; Tao J; Sun Y; Wang G; Li Y; Bian L; Goel R; Sartori S; Zhang Z; Angiolillo DJ; Cohen DJ; Gibson CM; Kastrati A; Krucoff M; Mehta SR; Ohman EM; Steg PG; Liu Y; Dangas G; Sharma S; Baber U; Mehran R Circ Cardiovasc Interv; 2022 Apr; 15(4):e009495. PubMed ID: 35317615 [TBL] [Abstract][Full Text] [Related]
15. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA; Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629 [TBL] [Abstract][Full Text] [Related]
16. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G; Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085 [TBL] [Abstract][Full Text] [Related]
17. Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor. Verdoia M; Nardin M; Gioscia R; Negro F; Marcolongo M; Suryapranata H; Kedhi E; De Luca G; Vascul Pharmacol; 2020 Sep; 132():106765. PubMed ID: 32681888 [TBL] [Abstract][Full Text] [Related]
18. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. Angiolillo DJ; Cao D; Baber U; Sartori S; Zhang Z; Dangas G; Mehta S; Briguori C; Cohen DJ; Collier T; Dudek D; Escaned J; Gibson CM; Gil R; Huber K; Kaul U; Kornowski R; Krucoff MW; Kunadian V; Moliterno DJ; Ohman EM; Oldroyd K; Sardella G; Sharma SK; Shlofmitz R; Weisz G; Witzenbichler B; Pocock S; Mehran R JACC Cardiovasc Interv; 2021 Jul; 14(13):1434-1446. PubMed ID: 34238553 [TBL] [Abstract][Full Text] [Related]
19. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422 [TBL] [Abstract][Full Text] [Related]
20. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]